Earnings calls

Poly Medicure concall ledger

Every earnings call for POLYMED — management tone, guidance, KPIs and promise tracking, quarter by quarter.

POLYMED · 6 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 25 May 2026Call held 25 May 2026

POLYMED Q4 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue₹1,875 cr+12% YoYStandalone EBITDA₹446 crStandalone EBITDA Margin26.8%

Consolidated Revenue (FY26) ₹1,875 cr (+12% YoY); Standalone EBITDA (FY26) ₹446 cr; Standalone EBITDA Margin (FY26) 26.8%. Consolidated revenue grew 12.3% YoY to INR1,875 crores for FY26.

Read full transcript & analysis

Q3 FY26Published 06 Feb 2026Call held 06 Feb 2026

POLYMED Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹494 cr+16% YoYOperating EBITDA Margin24.2%PAT₹71 crGross Margin68.4%

Revenue ₹494 cr (+16% YoY); Operating EBITDA Margin 24.2%; PAT ₹71 cr. Consolidated revenue reached ₹494 crores, representing a 16.4% YoY and 11.2% QoQ growth.

Read full transcript & analysis

Q2 FY26Published 10 Nov 2025Call held 10 Nov 2025

POLYMED Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹444 cr+6% YoYOperating EBITDA Margin26.8%PAT₹92 cr+5% YoYGross Margin69.4%+1% YoY

Revenue ₹444 cr (+6% YoY); Operating EBITDA Margin 26.8%; PAT ₹92 cr (+4% YoY). Consolidated Revenue for Q2 reached ₹444 crores, up 5.7% YoY and 10.1% QoQ.

Read full transcript & analysis

Q1 FY26Published 25 Sept 2025Call held 25 Sept 2025

POLYMED Q1 FY26 Earnings Call Transcript & Analysis

Citieffe Revenue17.3 million Euro+15% YoYCitieffe EBITDA3.1 million Euro+14% YoYCitieffe Gross Margin90%Citieffe EBITDA Margin17.9%Acquisition Enterprise Value31 million Euro

Citieffe Revenue (2024) 17.3 million Euro (+15% YoY); Citieffe EBITDA (2024) 3.1 million Euro (+14% YoY); Citieffe Gross Margin 90%. Acquisition of Citieffe Group (Italy) finalized with an Enterprise Value of €31 million, valued at approximately 10x 2024 EBITDA.

Read full transcript & analysis

Q4 FY25Published 07 May 2025Call held 07 May 2025

POLYMED Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹440 cr+17% YoYEBITDA₹119.5 cr+24% YoYEBITDA Margin27.1%PAT₹91.8 cr+34% YoY

Revenue ₹440 cr (+16% YoY); EBITDA ₹120 cr (+24% YoY); EBITDA Margin 27.1%. Consolidated Q4 revenue reached ₹440 crores, representing a 16.5% YoY growth.

Read full transcript & analysis

Q3 FY25Published 03 Feb 2025Call held 03 Feb 2025

POLYMED Q3 FY25 Earnings Call Transcript & Analysis

Revenue₹424 cr+25% YoYEBITDA₹116 cr+28% YoYEBITDA Margin27.4%PAT₹85 cr+31% YoYROCE23.9%

Revenue ₹424 cr (+25% YoY); EBITDA ₹116 cr (+28% YoY); EBITDA Margin 27.4%. Consolidated revenue grew 24.9% YoY to ₹424 crores in Q3 FY25.

Read full transcript & analysis